Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection

被引：12
|
作者：
Verburg, Frederik A. [1 ]
de Blois, Erik [1 ]
Koolen, Stijn [1 ,2 ,3 ]
Konijnenberg, Mark W. [1 ,4 ]
机构：
[1] Erasmus MC, Dept Radiol & Nucl Med, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands
[3] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Radboud UMC, Dept Radiol & Nucl Med, Nijmegen, Netherlands
来源：
EJNMMI PHYSICS | 2023年 / 10卷 / 01期
关键词：
Lu-177]Lu-DOTA-TATE; Lu-177]Lu-PSMA-617; Radionuclide therapy; Dosimetry; Terbium-161; PRRT;
D O I：
10.1186/s40658-023-00589-w
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Aim: To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617.Methods: Using established kinetic data for [Lu-177]Lu-DOTA-TATE and [Lu-177]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([Lu-177]Lu-DOTA-TATE: kidneys, spleen and liver, [Lu-177]Lu-PSMA-617: kidneys, liver and salivary glands) were calculated for Lu-177 and Tb-161.Results: For both DOTA-TATE and PSMA-617, the substitution of Lu-177 with Tb-161 results in an increase in the delivered dose per unit of activity to tumour tissue by 40%. If an equivalent non-target delivered dose is strived for in order not to increase toxicity, based on kidney absorbed dose, 7400 MBq Lu-177 per cycle should be substituted with 5400 MBq Tb-161 for DOTA-TATE and 5300 MBq of Tb-161 for PSMA-617.Conclusion: When substituting Lu-177 with Tb-161, activity conversion is necessary in order not to exceed non-target dose limits.
引用
收藏
页数：6
相关论文
共 21 条
  • [1] Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
    Frederik A. Verburg
    Erik de Blois
    Stijn Koolen
    Mark W. Konijnenberg
    EJNMMI Physics, 10
  • [2] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S373 - S373
  • [3] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S179 - S179
  • [4] PSMA Radioligand Therapy of Metastasized Prostate Cancer Using Lu-177 PSMA I&T and Lu-177 PSMA-617: First comparative Dosimetric Results
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S36 - S37
  • [5] Individual effective half-life in Lu-177 Dota-Tate therapy
    Fitschen, J.
    Knoop, B. O.
    Knapp, W. H.
    Geworski, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S339 - S339
  • [6] Preliminary Results of Lu-177 DOTA-TATE Therapy in Patients with Neuroendocrine Tumor
    Hekimsoy, T.
    Isgoren, S.
    Gorur, G. Daglioz
    Demir, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S596 - S596
  • [7] PSMA Radioligand Therapy (PRLT) using Lu-177 PSMA I&T and Lu-177 PSMA-617: Intra-individual comparison of kinetics and dosimetry
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S214
  • [8] Lu-177 DOTA-TATE for peptide receptor Radionuclide therapy (PRRT): Organ, tumor, and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S358 - S359
  • [9] Lu-177 DOTA-TATE for peptide receptor radionuclide therapy (PRRT): organ-, tumor- and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S338 - S339
  • [10] Dosimetry in peptide receptor Radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: Intra- and interpatient variability
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S178 - S179
123